A Phase 3 interventional study of Ubrogepant 100 mg and Placebo in Migraine, sponsored by AbbVie. Completed at 73 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-31.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing ubrogepant in Migraine Disorders — 2 open to participants now, 4 under way, 3 of them phase 3. ubrogepant · Migraine Disorders.
Among the 14 studies testing ubrogepant in Migraine Disorders, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 7 in phase 3, and was the 7th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →2 of the 14 studies testing ubrogepant in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Puerto Rico
Ages 6–17
AbbVie · Sites in United States, Puerto Rico
Ages 6–17
By country, each count listing its studies:
ubrogepant: first FDA approval 2019 (UBRELVY). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 518 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 507 across the 14 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 4 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 22nd largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2020, is one of 30 in phase 3, and was the 29th registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
2 of the studies testing ubrogepant in Migraine Disorders that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05125302Phase 3AbbVieStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | 2027-05 |
| NCT06417775Phase 3AbbVieStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing ubrogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to Treatment Sequence A will receive placebo to treat their first qualifying prodrome event and ubrogepant 100 mg to treat their second qualifying prodrome event
Drug: Ubrogepant 100 mg · Drug: Placebo
Participants randomized to Treatment Sequence B will receive ubrogepant 100 mg to treat their first qualifying prodrome event and placebo to treat their second qualifying prodrome event
Drug: Ubrogepant 100 mg · Drug: Placebo
For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours
For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours
Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose
The absence of a headache of moderate/severe intensity will be recorded by the participant in an electronic diary (eDiary) within 24 hours after taking double-blind study intervention during the prodrome in order to determine the attenuation of headache. The absence of moderate or severe headache are derived based on headache record and rescue use.
Time frame: 24 hours after taking double-blind study intervention during the prodrome
Percentage of Participants Reporting Absence of Headache of Moderate or Severe Intensity Within 48 Hours Post-dose
The absence of a headache of moderate or severe intensity will be recorded by the participant in an eDiary within 48 hours after taking double-blind study intervention during the prodrome in order to determine the prevention of headache
Time frame: 48 hours after taking double-blind study intervention during the prodrome
Percentage of Participants Reporting Improvement in the Ability to Function Normally Over 24 Hours Post-dose
The Functional Disability Scale (FDS) is a single item used to measure the participant's level to function normally. Participants will be asked to rate the performance of daily activities using 4 response options ranging from 0 (no disability, able to function normally) to 3 (severely impaired, cannot do all or most things, bed rest may be necessary) within 24 hours after taking double-blind study intervention during the prodrome
Time frame: 24 hours after taking double-blind study intervention during the prodrome
Percentage of Participants Reporting Absence of Headache of Any Intensity Within 24 Hours Post-dose
The absence of a headache of moderate/severe intensity will be recorded by the participant in an electronic diary (eDiary) within 24 hours after taking double-blind study intervention during the prodrome in order to determine the attenuation of headache. The absence of moderate or severe headache are derived based on headache record and rescue use.
Time frame: 24 hours after taking double-blind study intervention during the prodrome
| Milestone | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Started | 264 | 254 |
| Safety population | 247 | 233 |
| Completed | 223 | 215 |
| Not completed | 41 | 39 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Protocol violation | 5 | 2 |
| Withdrew: Lack of qualifying event | 25 | 27 |
| Withdrew: Non-compliance with study drug | 2 | 1 |
The absence of a headache of moderate/severe intensity will be recorded by the participant in an electronic diary (eDiary) within 24 hours after taking double-blind study intervention during the prodrome in order to determine the attenuation of headache. The absence of moderate or severe headache are derived based on headache record and rescue use.
| Participants | Placebo | Ubrogepant 100 mg |
|---|---|---|
| Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose | 121 | 190 |
The absence of a headache of moderate or severe intensity will be recorded by the participant in an eDiary within 48 hours after taking double-blind study intervention during the prodrome in order to determine the prevention of headache
| Participants | Placebo | Ubrogepant 100 mg |
|---|---|---|
| Percentage of Participants Reporting Absence of Headache of Moderate or Severe Intensity Within 48 Hours Post-dose | 100 | 159 |
The Functional Disability Scale (FDS) is a single item used to measure the participant's level to function normally. Participants will be asked to rate the performance of daily activities using 4 response options ranging from 0 (no disability, able to function normally) to 3 (severely impaired, cannot do all or most things, bed rest may be necessary) within 24 hours after taking double-blind study intervention during the prodrome
| Participants | Placebo | Ubrogepant 100 mg |
|---|---|---|
| 1 Hour — Responder | 96 | 107 |
| 1 Hour — Nonresponder | 336 | 311 |
| 2 Hours — Responder | 110 | 156 |
| 2 Hours — Nonresponder | 311 | 266 |
| 3 Hours — Responder | 150 | 199 |
| 3 Hours — Nonresponder | 269 | 213 |
| 4 Hours — Responder | 173 | 245 |
| 4 Hours — Nonresponder | 244 | 170 |
| 6 Hours — Responder | 210 | 266 |
| 6 Hours — Nonresponder | 190 | 129 |
| 8 Hours — Responder | 239 | 291 |
| 8 Hours — Nonresponder | 155 | 97 |
| 24 Hours — Responder | 342 | 367 |
| 24 Hours — Nonresponder | 62 | 46 |
The absence of a headache of moderate/severe intensity will be recorded by the participant in an electronic diary (eDiary) within 24 hours after taking double-blind study intervention during the prodrome in order to determine the attenuation of headache. The absence of moderate or severe headache are derived based on headache record and rescue use.
| Participants | Placebo | Ubrogepant 100 mg |
|---|---|---|
| Percentage of Participants Reporting Absence of Headache of Any Intensity Within 24 Hours Post-dose | 61 | 103 |
Collected over From first dose through 30 days after the last dose of study drug (approximately 30 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/462 (0%) | 1/462 (0.2%) | 35/462 (7.6%) |
| Ubrogepant 100 mg | 0/456 (0%) | 0/456 (0%) | 50/456 (11%) |
| Event | Placebo | Ubrogepant 100 mg |
|---|---|---|
| RHABDOMYOLYSISMusculoskeletal and connective tissue disorders | 1/462 | 0/456 |
| Event | Placebo | Ubrogepant 100 mg |
|---|---|---|
| NAUSEAGastrointestinal disorders | 17/462 | 24/456 |
| DIZZINESSNervous system disorders | 14/462 | 11/456 |
| FATIGUEGeneral disorders | 7/462 | 12/456 |
| SOMNOLENCENervous system disorders | 5/462 | 11/456 |
Safety Population consists of all treated participants who take at least 1 administration of study intervention
| Age, Continuous(years) | Treatment Sequence A | Treatment Sequence B | Total |
|---|---|---|---|
| Mean | 41.7 ± 12.63 | 42.9 ± 13.10 | 42.3 ± 12.86 |
| Age, Customized(Participants) | Treatment Sequence A | Treatment Sequence B | Total |
|---|---|---|---|
| < 20 | 5 | 2 | 7 |
| 20 - 29 | 42 | 38 | 80 |
| 30 - 39 | 62 | 60 | 122 |
| 40 - 49 | 68 | 64 | 132 |
| 50 - 59 | 48 | 37 | 85 |
| 60 - 69 | 18 | 28 | 46 |
| >= 70 | 4 | 4 | 8 |
| Sex: Female, Male(Participants) | Treatment Sequence A | Treatment Sequence B | Total |
|---|---|---|---|
| Female | 216 | 205 | 421 |
| Male | 31 | 28 | 59 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence A | Treatment Sequence B | Total |
|---|---|---|---|
| Hispanic or Latino | 17 | 15 | 32 |
| Not Hispanic or Latino | 229 | 216 | 445 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Treatment Sequence A | Treatment Sequence B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 7 | 4 | 11 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 22 | 15 | 37 |
| White | 214 | 209 | 423 |
| More than one race | 2 | 4 | 6 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing, please refer to the link below
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · vivli.org
Ran from Aug 2020 to primary completion in Apr 2022, 19 months.
Results were first posted in May 2023, 1 year 1 month after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 19 months is close to that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ubrogepant